|
|
Gene Symbol |
SST |
|
Aliases |
SMST |
|
Entrez Gene ID |
|
|
Gene Name |
Somatostatin |
|
Chromosomal Location |
3q27.3 |
|
HGNC ID |
|
|
Summary |
The hormone somatostatin has active 14 aa and 28 aa forms that are produced by alternate cleavage of the single preproprotein encoded by this gene. Somatostatin is expressed throughout the body and inhibits the release of numerous secondary hormones by binding to high-affinity G-protein-coupled somatostatin receptors. This hormone is an important regulator of the endocrine system through its interactions with pituitary growth hormone, thyroid stimulating hormone, and most hormones of the gastrointestinal tract. Somatostatin also affects rates of neurotransmission in the central nervous system and proliferation of both normal and tumorigenic cells. [provided by RefSeq, Jul 2008]
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Somatostatin, growth hormone release-inhibiting factor, prepro-somatostatin, somatostatin-14, somatostatin-28 |
|
Function |
[Somatostatin-14]: Inhibits the secretion of pituitary hormones, including that of growth hormone/somatotropin (GH1), PRL, ACTH, luteinizing hormone (LH) and TSH. Also impairs ghrelin- and GnRH-stimulated secretion of GH1 and LH; the inhibition of ghrelin-stimulated secretion of GH1 can be further increased by neuronostatin. .; [Neuronostatin]: May enhance low-glucose-induced glucagon release by pancreatic alpha cells (By similarity). This effect may be mediated by binding to GPR107 and PKA activation (By similarity). May regulate cardiac contractile function (By similarity). May compromise cardiomyocyte viability (By similarity). In the central nervous system, may impair memory retention and may affect hippocampal excitability (By similarity). May also have anxiolytic and anorexigenic effects (By similarity). May play a role in arterial pressure regulation (By similarity). May inhibit basal, but not ghrelin- or GnRH-stimulated secretion of GH1 or LH, but does not affect the release of other pituitary hormones, including PRL, ACTH, FSH or TSH. Potentiates inhibitory action of somatostatin on ghrelin-stimulated secretion of GH1, but not that on GnRH-stimulated secretion of LH (PubMed:29615476). |
|
|
UniProt |
|
|
PDB |
|
|
Pfam |
Pfam Accession |
Pfam ID |
PF03002 |
Somatostatin |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000349960 |
P60709 |
P60709 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Atonic seizures |
|
Digestive System Diseases |
Gastric Varix |
|
Esophageal Varices |
|
Pancreatitis |
|
Endocrine System Diseases |
PCOS |
|
Neoplasms |
Esophagus Neoplasm |
|
Barrett Esophagus |
|
Vipoma |
|
Barrett Epithelium |
|
Pancreatic Neoplasm |
|
Pancreatic Cholera |
|
Nervous System Diseases |
Seizures |
|
Jacksonian Seizure |
|
Psychiatric/Brain disorders |
Mental Depression |
|
Schizoaffective Disorder |
|
Schizophrenia |
|
Mood Disorders |
|
Bipolar Disorder |
|
Reproductive disorders |
Endometriosis |
|
Endometrioma |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
beta-EP, Dyn A |
PCOS |
|
|
Related
|
Group 1 (LH/ FSH > or = 3, n = 30); group 2 (LH/FSH < 3, n = 25), and controls (n = 15) |
The data suggest endogenously lower SS, higher beta-EP and Dyn A may contribute to the elevation of LH and insulin secretions in PCOS. |
|
beta-EP, Dyn A |
PCOS |
|
|
Related
|
15 normally menstruating women (control) and 30 PCOS women with LH/follicle stimulating hormone (FSH) ratio greater than 3 (group 1) and 25 PCOS subjects with the ratio < 3 (group 2) |
These data suggested lower endogenous SS, higher beta-EP and Dyn A may lead to elevation of LH and insulin secretions in patients with PCOS. |
|
|
|
|